Skip to Main Content

BioNTech SE (NASDAQ: BNTX) Securities Fraud Class Action

View Complaint
CompanyBioNTech SE
CourtUnited States District Court for the Southern District of New York
Case Number24-cv-05310
JudgeHonorable Katherine Polk Failla
Class PeriodMarch 30, 2022 through October 13, 2023
Security TypeAmerican Depositary Shares

Case Background:

This is a federal securities fraud class action lawsuit on behalf of those who purchased or otherwise acquired BioNTech SE (“BioNTech”) (NASDAQ: BNTX) American Depositary Shares between March 30, 2022 and October 13, 2023, inclusive (the “Class Period”).  

The complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements regarding the company's business, operations, and prospects. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (1) BioNTech overstated demand for Comirnaty and/or its commercial prospects; (2) the company and/or Pfizer had accumulated excess inventory of raw materials for Comirnaty, as well as COVID-19 vaccine doses adapted to other, non-XBB.1.5 variants that were produced at risk; (3) accordingly, BioNTech was at an increased risk of recording significant inventory write-offs and other charges related to Comirnaty; and (4) as a result, Defendants' public statements were materially false and/or misleading at all relevant times.

Current Status of Case:

On September 30, 2025, the Court granted Defendants’ Motion to Dismiss the Amended Complaint. This action has concluded.

If you wish to discuss this action or have any questions, please contact Kessler Topaz Meltzer & Check, LLP: Jon Naji, Esq. (484) 270-1453; toll-free at (844) 887-9500; or via e-mail at info@ktmc.com. If you would like additional information about the suit, please click on the link "Submit Your Information" above and fill out the form as promptly as possible.

Please complete this form relating to your transactions for BioNTech SE (NASDAQ: BNTX) securities between March 30, 2022 and October 13, 2023, both dates inclusive (the “Class Period”).

Click here to print a PDF of this form

SUBMIT YOUR INFORMATION
* Denotes required field
Date
# of Shares
Price per Share
Date
Principal Amount
Amount Paid
Series or CUSIP
Date
# of Contracts
Price per Contract
Exercise Price
Expiration Date
Did you purchase shares of BioNTech SE prior to the Class Period?
Are you a current or former employee of BioNTech SE?
The submission of this form does not create an attorney-client relationship, nor an obligation on the part of Kessler Topaz or you to file a lead plaintiff motion in this matter. Any information you submit will be maintained as confidential. If Kessler Topaz, in its sole discretion, believes that you might be an appropriate lead plaintiff candidate, Kessler Topaz will contact you to discuss the matter and whether to establish an attorney client relationship. By signing this form you are authorizing us to contact you regarding this case and/or future cases.
I agree to the KTMC disclaimer
I would like to receive new case alerts by email